Health Bulletin Haiti: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Bulletin Haiti.

Press releases published on June 3, 2026

Jun. 3, 2026

SweetWater Brewing Unveils Atlanta-Wide Soccer Celebration as Global Fans Descend on the City This Summer

Indeterminate GlobeNewswire

Jun. 3, 2026

Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

Indeterminate GlobeNewswire

Jun. 3, 2026

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Indeterminate GlobeNewswire

Jun. 3, 2026

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Indeterminate GlobeNewswire

Jun. 3, 2026

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

Indeterminate GlobeNewswire

Jun. 3, 2026

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

Indeterminate GlobeNewswire

Jun. 3, 2026

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

Indeterminate GlobeNewswire

Jun. 3, 2026

Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China

Indeterminate GlobeNewswire

Jun. 3, 2026

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Indeterminate GlobeNewswire

Jun. 3, 2026

Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Indeterminate GlobeNewswire

Jun. 3, 2026

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

Indeterminate GlobeNewswire

Jun. 3, 2026

Pennant Expands Senior Living Presence with Pleasant Hill, California Community 

Indeterminate GlobeNewswire

Jun. 3, 2026

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Indeterminate GlobeNewswire

Jun. 3, 2026

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study

Indeterminate GlobeNewswire

Jun. 3, 2026

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

Indeterminate GlobeNewswire

Jun. 3, 2026

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Indeterminate GlobeNewswire

Jun. 3, 2026

Making Democracy Cute Again: Cutest Pets on Parliament Hill Crowns 2026 Winners

Indeterminate GlobeNewswire

Jun. 3, 2026

Rendre la démocratie attirante de nouveau : le concours « Les animaux de compagnie les plus mignons sur la Colline du Parlement » dévoile ses lauréats 2026

Indeterminate GlobeNewswire

Jun. 3, 2026

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Indeterminate GlobeNewswire

Jun. 3, 2026

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Indeterminate GlobeNewswire